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Ciproﬂ  oxacin 
Resistance in 
Neisseria 
meningitidis, 
France 
To the Editor: Infections with 
Neisseria meningitidis may occur as 
outbreaks or epidemics. Consequently, 
chemoprophylaxis for contacts is gen-
erally recommended. Ciproﬂ  oxacin is 
frequently used in adults in a conve-
nient 1-dose regimen (1). Resistance to 
this antimicrobial drug in N. meningiti-
dis is rare (MIC>0.06 mg/L) and has 
been reported only in sporadic cases 
in Greece, France, Australia, Spain, 
Argentina and Hong Kong Special 
Administrative Region, People’s Re-
public of China (2–5). However, recent 
reports have described ciproﬂ  oxacin-
resistant (Cip-R) serogroup A menin-
gococci from 2 outbreaks in Delhi, 
India, (6) and a cluster of 3 serogroup 
B meningococci in the United States 
(7). This information is of concern be-
cause of the high epidemic potential of 
serogroup A isolates, lack of vaccine 
against serogroup B meningococci, and 
possible horizontal Cip-R gene transfer 
to other meningococcal isolates.
Experimental work was conduct-
ed in the Neisseria Unit of the Institut 
Pasteur in Paris. We screened all clini-
cal N. meningitidis isolates received at 
the French National Reference Cen-
ter for Meningococci in Paris since 
1999 for ciproﬂ  oxacin resistance. Of 
these isolates, 4,900 were from France 
and 246 were from African countries 
(Burkina Faso, Cameroon, Central Af-
rican Republic, Côte d’Ivoire, Mada-
gascar, Niger, Rwanda, Senegal, and 
Tunisia). Only 3 isolates tested were 
resistant to ciproﬂ   oxacin (MICs = 
0.19 mg/L), and all were isolated from 
cases of invasive disease in France. 
Two serogroup A, serotype 4, 
serosubtype P1.9, Cip-R isolates be-
longed to different sequence types 
(STs), ST-7 (Cip-R1) and ST-4789 
(Cip-R2), although they belonged to 
the same clonal complex (ST-5/sub-
group III). Cip-R1, which showed 
decreased susceptibility to penicillin, 
was isolated in 2004 from the blood 
of a 7-year-old girl. This isolate was 
most likely imported from Africa. 
Cip-R2 was isolated from the cere-
brospinal ﬂ  uid of a 77-year-old man 
who had arrived in France from India 
in 2006. The ST of this isolate (ST-
4789) is the same as the ST of isolates 
from an outbreak in Bangladesh and 
similar to isolates from an outbreak 
in India (6; http://neisseria.org/nm/
typing/mlstdb). Cip-R3 (serogroup 
W-135, nontypeable, subtype P1.5), 
which was isolated from blood and 
cerebrospinal ﬂ  uid of an 82-year-old 
woman in 2006, belonged to a new 
ST (ST-6361). Current ciproﬂ  oxacin 
resistance has not been documented 
among invasive W-135 meningococ-
cal isolates since 2 W-135 resistant 
meningococci were isolated from 
sputum samples of elderly patients in 
Spain (3).
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To investigate the mechanism of 
resistance in the isolates, fragments of 
gyrA (847 bp) and parC (822 bp) genes 
were ampliﬁ  ed by using primers gyrA-
1F (5′-gttttcccagtcacgacgttgtaATGA
CCGACGCAACCATCCGCCAC-3′) 
and gyrA-1R (5′-ttgtgagcggataacaattt
cCCAGCTTGGCTTTGTTGACCTG
ATAG-3′), and parC-1F (5′-gttttcccag
tcacgacgttgtaATGAATACGCAAGC
GCACGCCCCA-3′) and parC-1R (5′- 
ttgtgagcggataacaatttcGGAATTGGC
GTTCGGCGGCAGCTC-3′), respec-
tively (sequences in lower case letters 
are adaptors for universal forward and 
reverse sequences were added for se-
quencing after ampliﬁ  cation).  Prim-
ers used for ampliﬁ  cation of the parE 
gene were as described (8).
Sequencing of fragments of 
gyrA, parC, and parE genes showed 
a mutation in the gyrA gene in the 3 
Cip-R isolates resulting in a Thr91 → 
Ile substitution. Cip-R1 also showed 
additional alterations of Asn103 → 
Asp, Ile111 → Val, and Val120 → Ile, 
which were described for meningo-
coccal isolates (3). Sequences of parC 
and parE genes were the same as in 
a ciproﬂ  oxacin-susceptible  isolate 
tested. The association of the Cip-R 
phenotype with mutations in gyrA was 
conﬁ  rmed by transformation into the 
susceptible isolate by using appropri-
ate PCR products (9). In addition to 
the common Thr91 → Ile substitution, 
the 3 Cip-R isolates were distinguish-
able by additional gyrA alterations or 
phenotypic and genotypic character-
istics. This ﬁ  nding suggests indepen-
dent events and argues against clonal 
expansion of Cip-R meningococci.
Serogroup A meningococcal iso-
lates in France are rare and mostly 
imported. Lack of detection of cip-
roﬂ  oxacin resistance among African 
isolates tested in this study may be 
caused by the relatively low number 
of these isolates (n = 246). Therefore, 
surveillance of antimicrobial drug 
susceptibility of meningococcal iso-
lates should be enhanced by using 
molecular approaches that can also 
be used as nonculture techniques. 
This molecular approach will be use-
ful in countries with limited access to 
classic microbiologic culture–based 
methods. Reports of invasive cases 
caused by W-135 Cip-R meningo-
cocci should alert physicians who 
use quinolones to treat respiratory 
infections in elderly persons. This 
age group is affected most often by 
invasive meningococcal pneumonia 
and 54.5% of such cases are caused 
by W-135 meningococci (10).
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Rare 
Cryptosporidium 
hominis Subtype 
Associated with 
Aquatic Center Use
To the Editor: Cryptosporidiosis 
is the most frequently reported gas-
trointestinal illness in outbreaks as-
sociated with treated (disinfected) 
recreational water venues in the Unit-
ed States (1). In 2003, an increased 
number of cryptosporidiosis cases 
occurred in the Tri-Cities area of the 
Lower Mainland region (near Van-
couver), in British Columbia, Canada. 
Although all cases were associated 
with the use of a community aquatic 
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